← Search & browse all drugs
CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS › Angiotensin II receptor blockers (ARBs), other combinations
valsartan and sacubitril
C09DX04
Forms & Strengths
- Tablets: 49mg/51mg, 97mg/103mg, 145mg/155mg valsartan/sacubitril
- Film-coated tablets
Adult Dosing
- Initial dose: 49mg/51mg twice daily
- Target dose: 97mg/103mg twice daily
- Max dose: 145mg/155mg twice daily
- Dose titration at 2-4 week intervals
Pediatric Dosing
- Not established for pediatric patients under 18 years
- Limited data in pediatric patients
Indications
- Treatment of heart failure (HF) with reduced ejection fraction (HFrEF)
- To reduce the risk of CV death and hospitalization due to HF
Mechanism of Action
- Angiotensin II receptor blocker (ARB) and neprilysin inhibitor
- Increases levels of natriuretic peptides
- Reduces vasoconstrictive and sodium-retentive effects of angiotensin II
Contraindications
- Hypersensitivity to valsartan, sacubitril, or any component
- Use with aliskiren in diabetic patients
- Use with ACE inhibitors, or in patients with a history of angioedema
Adverse Reactions
- Hypotension
- Hyperkalemia
- Cough
- Dizziness
- Renal impairment
- Angioedema
Drug Interactions
- Concomitant use with ACE inhibitors increases risk of angioedema
- Aliskiren increases risk of hyperkalemia, hypotension, and renal impairment
- Potassium-sparing diuretics increase risk of hyperkalemia
- Lithium levels may increase with concomitant use
Curated Content: Needs Vetting Before Put to Clinical Use